Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Travere Therapeutics, Inc.TVTX · Entity 1562 | Chief Legal Officer and GC | September 15, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Travere Therapeutics, Inc.
Report date September 15, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 142,889 |
Reported balance
After 2026-09-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-15 · Exercise / conversion · Acquired 37,500 · Balance 142,889 F1: Includes 178 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026. |
| Common StockSEC Table I · non-derivative | Direct | 120,963 |
Reported balance
After 2026-09-15 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-15 · Sale · Disposed 21,926 · Balance 120,963 F2: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F3: The weighted average sale price for the transaction reported was $62.0255, and the range of prices were between $61.44 and $62.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| Common StockSEC Table I · non-derivative | Direct | 107,089 |
Reported balance
After 2026-09-15 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-09-15 · Sale · Disposed 13,874 · Balance 107,089 F2: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F4: The weighted average sale price for the transaction reported was $62.6326, and the range of prices were between $62.44 and $63.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| Common StockSEC Table I · non-derivative | Direct | 105,689 |
Reported balance
After 2026-09-15 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-09-15 · Sale · Disposed 1,400 · Balance 105,689 F2: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F5: The weighted average sale price for the transaction reported was $63.6902, and the range of prices were between $63.59 and $63.85. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| Common StockSEC Table I · non-derivative | Direct | 105,389 |
Reported balance
After 2026-09-15 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2026-09-15 · Sale · Disposed 300 · Balance 105,389 F2: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.46 · Expires 2030-01-31 | Direct | 0 |
Reported balance
After 2026-09-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-15 · Exercise / conversion · Disposed 37,500 · Balance 0 F6: The stock option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 178 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026.
F2: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F3: The weighted average sale price for the transaction reported was $62.0255, and the range of prices were between $61.44 and $62.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4: The weighted average sale price for the transaction reported was $62.6326, and the range of prices were between $62.44 and $63.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F5: The weighted average sale price for the transaction reported was $63.6902, and the range of prices were between $63.59 and $63.85. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F6: The stock option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2026 Filed Sep 18, 2026 01:32 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 37,500 | $0.00 Strike: $15.46 | $0.00 |
DisclosureSEC source: 0001283303-26-000010 · form4-09182026_010948.xml · derivative · entry 6 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2030-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| September 15, 2026 Filed Sep 18, 2026 01:32 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 300 | $65.31 | $19,593.00 |
DisclosureSEC source: 0001283303-26-000010 · form4-09182026_010948.xml · nonDerivative · entry 5 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,389 F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 15, 2026 Filed Sep 18, 2026 01:32 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 1,400 | $63.69 | $89,166.28 |
DisclosureSEC source: 0001283303-26-000010 · form4-09182026_010948.xml · nonDerivative · entry 4 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,689 F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F5 · price: The weighted average sale price for the transaction reported was $63.6902, and the range of prices were between $63.59 and $63.85. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| September 15, 2026 Filed Sep 18, 2026 01:32 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 13,874 | $62.63 | $868,964.69 |
DisclosureSEC source: 0001283303-26-000010 · form4-09182026_010948.xml · nonDerivative · entry 3 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,089 F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F4 · price: The weighted average sale price for the transaction reported was $62.6326, and the range of prices were between $62.44 and $63.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| September 15, 2026 Filed Sep 18, 2026 01:32 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 21,926 | $62.03 | $1,359,971.11 |
DisclosureSEC source: 0001283303-26-000010 · form4-09182026_010948.xml · nonDerivative · entry 2 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,963 F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F3 · price: The weighted average sale price for the transaction reported was $62.0255, and the range of prices were between $61.44 and $62.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| September 15, 2026 Filed Sep 18, 2026 01:32 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 37,500 | $15.46 | $579,750.00 |
DisclosureSEC source: 0001283303-26-000010 · form4-09182026_010948.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,889 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 178 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026. Read SEC document |
| May 06, 2026 Filed May 7, 2026 00:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 2,076 | $43.95 | $91,240.20 |
DisclosureSEC source: 0001283303-26-000009 · form4-05062026_080511.xml · nonDerivative · entry 5 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,211 F4 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. Read SEC document |
| May 05, 2026 Filed May 7, 2026 00:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 2,174 | $46.65 | $101,417.10 |
DisclosureSEC source: 0001283303-26-000009 · form4-05062026_080511.xml · nonDerivative · entry 4 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,287 F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionPerformance-based restricted stock units · Derivative | 4,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001283303-26-000009 · form4-05062026_080511.xml · derivative · entry 8 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,250 Underlying: Common Stock · 4,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions. F2 · kind: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. F2 · derivative.exercise_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. F2 · derivative.expiration_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantPerformance-based restricted stock units · Derivative | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001283303-26-000009 · form4-05062026_080511.xml · derivative · entry 7 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires not disclosed F6 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Issuer's common stock at target, subject to adjustment based on the achievement of applicable performance conditions. F2 · kind: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. F2 · derivative.exercise_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. F2 · derivative.expiration_date: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $17.96 | $0.00 |
DisclosureSEC source: 0001283303-26-000009 · form4-05062026_080511.xml · derivative · entry 6 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2029-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 4,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001283303-26-000009 · form4-05062026_080511.xml · nonDerivative · entry 3 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,461 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: On January 31, 2024, the Reporting Person was granted performance restricted stock units (PSUs) covering 8,500 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. If any such milestone is achieved on a pre-specified accelerated timeline, up to 50% additional shares attributable to such milestone achievement could vest under these PSU grants, with such additional potential shares to vest at a later date in furtherance of retention objectives. On May 4, 2026, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2026 that a performance criterion related to cumulative FILSPARI net revenue had been achieved, and contingent on continuous service by the Reporting Person, on January 31, 2027 an additional 25% of such PSUs will vest due to the timing of the achievement of such cumulative FILSPARI net revenue performance criterion. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 20,000 | $45.00 | $900,000.00 |
DisclosureSEC source: 0001283303-26-000009 · form4-05062026_080511.xml · nonDerivative · entry 2 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,211 F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person. Read SEC document |
| May 04, 2026 Filed May 7, 2026 00:00 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 20,000 | $17.96 | $359,200.00 |
DisclosureSEC source: 0001283303-26-000009 · form4-05062026_080511.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 15, 2026 Filed Apr 16, 2026 01:47 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 1,559 | $42.53 | $66,304.27 |
DisclosureSEC source: 0001283303-26-000008 · form4-04162026_010431.xml · nonDerivative · entry 8 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,211 F4 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F6 · price: The weighted average sale price for the transaction reported was $42.53, and the range of prices were between $42.335 and $42.66. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 15, 2026 Filed Apr 16, 2026 01:47 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 5,226 | $41.62 | $217,506.12 |
DisclosureSEC source: 0001283303-26-000008 · form4-04162026_010431.xml · nonDerivative · entry 7 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,770 F4 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. F5 · price: The weighted average sale price for the transaction reported was $41.62, and the range of prices were between $41.255 and $42.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 01:47 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 20,000 | $0.00 Strike: $17.96 | $0.00 |
DisclosureSEC source: 0001283303-26-000008 · form4-04162026_010431.xml · derivative · entry 11 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 01:47 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $19.08 | $0.00 |
DisclosureSEC source: 0001283303-26-000008 · form4-04162026_010431.xml · derivative · entry 10 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2027-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 01:47 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 7,500 | $0.00 Strike: $15.46 | $0.00 |
DisclosureSEC source: 0001283303-26-000008 · form4-04162026_010431.xml · derivative · entry 9 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 7,500 shares Expires 2030-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 01:47 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 7,215 | $41.93 | $302,516.29 |
DisclosureSEC source: 0001283303-26-000008 · form4-04162026_010431.xml · nonDerivative · entry 6 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,996 F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 01:47 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 37,500 | $41.07 | $1,540,125.00 |
DisclosureSEC source: 0001283303-26-000008 · form4-04162026_010431.xml · nonDerivative · entry 5 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,211 F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 01:47 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 7,500 | $15.46 | $115,950.00 |
DisclosureSEC source: 0001283303-26-000008 · form4-04162026_010431.xml · nonDerivative · entry 4 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,711 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 01:47 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 20,000 | $17.96 | $359,200.00 |
DisclosureSEC source: 0001283303-26-000008 · form4-04162026_010431.xml · nonDerivative · entry 3 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 01:47 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 10,000 | $19.08 | $190,800.00 |
DisclosureSEC source: 0001283303-26-000008 · form4-04162026_010431.xml · nonDerivative · entry 2 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2026 Filed Apr 16, 2026 01:47 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001283303-26-000008 · form4-04162026_010431.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 119,211 F1 · kind: On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:55 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $15.46 | $0.00 |
DisclosureSEC source: 0001283303-26-000007 · form4-04022026_050408.xml · derivative · entry 3 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 10,000 shares Expires 2030-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:55 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 10,000 | $30.00 | $300,000.00 |
DisclosureSEC source: 0001283303-26-000007 · form4-04022026_050408.xml · nonDerivative · entry 2 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,211 F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 31, 2020. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:55 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 10,000 | $15.46 | $154,600.00 |
DisclosureSEC source: 0001283303-26-000007 · form4-04022026_050408.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $19.08 | $0.00 |
DisclosureSEC source: 0001283303-26-000006 · form4-03182026_040301.xml · derivative · entry 3 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 10,000 | $28.09 | $280,861.00 |
DisclosureSEC source: 0001283303-26-000006 · form4-03182026_040301.xml · nonDerivative · entry 2 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,211 F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 4, 2017 with an expiration date of January 4, 2027. F2 · price: The weighted average sale price for the transaction reported was $28.0861, and the range of prices were between $27.66 and $28.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 10,000 | $19.08 | $190,800.00 |
DisclosureSEC source: 0001283303-26-000006 · form4-03182026_040301.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:10 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $19.08 | $0.00 |
DisclosureSEC source: 0001283303-26-000005 · form4-02192026_040201.xml · derivative · entry 4 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2027-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:10 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 4,321 | $28.26 | $122,120.10 |
DisclosureSEC source: 0001283303-26-000005 · form4-02192026_040201.xml · nonDerivative · entry 3 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,211 F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 4, 2017 with an expiration date of January 4, 2027. F3 · price: The weighted average sale price for the transaction reported was $28.262, and the range of prices were between $28.09 and $28.50. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:10 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 5,679 | $27.50 | $156,195.22 |
DisclosureSEC source: 0001283303-26-000005 · form4-02192026_040201.xml · nonDerivative · entry 2 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,532 F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 4, 2017 with an expiration date of January 4, 2027. F2 · price: The weighted average sale price for the transaction reported was $27.504, and the range of prices were between $27.01 and $27.83. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:10 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 10,000 | $19.08 | $190,800.00 |
DisclosureSEC source: 0001283303-26-000005 · form4-02192026_040201.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2026 Filed Feb 5, 2026 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 509 | $32.74 | $16,664.66 |
DisclosureSEC source: 0001283303-26-000003 · form4-02052026_040205.xml · nonDerivative · entry 2 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,211 F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. F3 · price: The weighted average sale price for the transaction reported was $32.74, and the range of prices were between $32.64 and $32.90. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 04, 2026 Filed Feb 5, 2026 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 2,485 | $32.07 | $79,693.95 |
DisclosureSEC source: 0001283303-26-000003 · form4-02052026_040205.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,720 F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. F2 · price: The weighted average sale price for the transaction reported was $32.07, and the range of prices were between $31.63 and $32.61. Upon request by the SEC staff, the Issuer, or any security holder of theIssuer, full information regarding the number of shares sold at each price will be provided. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 02:30 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 7,175 | $32.12 | $230,461.00 |
DisclosureSEC source: 0001283303-26-000002 · form4-02032026_090203.xml · nonDerivative · entry 2 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,205 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 31, 2026 Filed Feb 4, 2026 02:30 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantEmployee stock option (right to buy) · Derivative | 66,960 | $0.00 Strike: $33.10 | $0.00 |
DisclosureSEC source: 0001283303-26-000002 · form4-02032026_090203.xml · derivative · entry 3 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,960 Underlying: Common Stock · 66,960 shares Expires 2036-01-31 F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| January 31, 2026 Filed Feb 4, 2026 02:30 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 25,110 | $0.00 | $0.00 |
DisclosureSEC source: 0001283303-26-000002 · form4-02032026_090203.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,380 F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. Read SEC document |
| January 20, 2026 Filed Jan 21, 2026 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $19.08 | $0.00 |
DisclosureSEC source: 0001283303-26-000001 · form4-01212026_040109.xml · derivative · entry 3 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 10,000 shares Expires 2027-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| January 20, 2026 Filed Jan 21, 2026 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 10,000 | $27.34 | $273,420.00 |
DisclosureSEC source: 0001283303-26-000001 · form4-01212026_040109.xml · nonDerivative · entry 2 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,270 F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 4, 2017 with an expiration date of January 4, 2027. F3 · price: The weighted average sale price for the transaction reported was $27.3420, and the range of prices were between $26.910 and $27.590. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| January 20, 2026 Filed Jan 21, 2026 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 10,000 | $19.08 | $190,800.00 |
DisclosureSEC source: 0001283303-26-000001 · form4-01212026_040109.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,270 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 392 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 28, 2025. Read SEC document |
| September 22, 2025 Filed Sep 24, 2025 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 10,000 | $0.00 Strike: $19.08 | $0.00 |
DisclosureSEC source: 0001283303-25-000005 · form4-09242025_040903.xml · derivative · entry 3 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 10,000 shares Expires 2027-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| September 22, 2025 Filed Sep 24, 2025 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 10,000 | $25.00 | $250,000.00 |
DisclosureSEC source: 0001283303-25-000005 · form4-09242025_040903.xml · nonDerivative · entry 2 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,878 F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 4, 2017 with an expiration date of January 4, 2027. Read SEC document |
| September 22, 2025 Filed Sep 24, 2025 20:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 10,000 | $19.08 | $190,800.00 |
DisclosureSEC source: 0001283303-25-000005 · form4-09242025_040903.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,878 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 396 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 31, 2025. Read SEC document |
| May 05, 2025 Filed May 6, 2025 01:51 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 4,920 | $21.05 | $103,566.00 |
DisclosureSEC source: 0001415889-25-012054 · form4-05062025_010531.xml · nonDerivative · entry 2 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,482 F3 · kind: This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. Read SEC document |
| May 02, 2025 Filed May 6, 2025 01:51 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionPerformance-based restricted stock units · Derivative | 4,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-012054 · form4-05062025_010531.xml · derivative · entry 3 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,920 Underlying: Common Stock · 4,920 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the common stock of the Issuer. F1 · kind: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved F1 · derivative.exercise_date: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved F1 · derivative.expiration_date: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved Read SEC document |
| May 02, 2025 Filed May 6, 2025 01:51 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | Exercise / conversionCommon Stock | 4,920 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-012054 · form4-05062025_010531.xml · nonDerivative · entry 1 REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,402 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 9,840 shares of the Issuer's common stock, to vest upon the satisfaction of certain performance criteria. On May 2, 2025, 50% of the PSUs vested upon the Issuer's confirmation following the release of its financial results for the quarter ended March 31, 2025 that a performance criterion related to cumulative FILSPARI net revenue had been achieved F2 · price: Each PSU represents a contingent right to receive one share of the common stock of the Issuer. Read SEC document |
| February 12, 2025 Filed Feb 13, 2025 02:28 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 8,000 | $23.53 | $188,240.00 |
DisclosureSEC source: 0001415889-25-003823 · form4-02132025_020224.xml · nonDerivative · entry 2 REED ELIZABETH E · CIK 0001283303 · SVP, GC & CORPORATE SECRETARY 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,482 F3 · kind: This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of the PSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.